Skip to main content
Premium Trial:

Request an Annual Quote

PROOF, AllerGen Team on Allergy PGx

NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) has teamed up with the Allergy, Genes and Environment Network of Centres of Excellence (AllerGen NCE) to develop blood-based tests intended to be used in clinical trials of drugs for allergic diseases.

The Canadian centers said they will apply PROOF's biomarker development expertise to blood samples obtained from AllerGen in an effort to identify molecular signals that predict chronic inflammatory responses in allergic asthmatic adults. The goal is to find biomarkers that can be used for effectively monitoring therapeutics being developed for allergic asthma.

The partners expects to complete the development and validation of a biomarker panel to predict an asthmatic individual's response to allergen exposure, as well as a panel to diagnose late allergic response by early 2014.

Among several partnerships it has already formed this year, Vancouver, British Columbia-based PROOF is working with Adiga Life Sciences to identify proteomic and genomic biomarkers for monitoring the effectiveness of allergy vaccines.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.